PRPS1 S103T

CI-VAR-00003973Explore in graph →CIViC 2927

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
B Lymphoblastic Leukemia/Lymphoma4
PRPS1 S103T	(prognostic)	Prognostic	C	Supports Poor Outcome	3	submitted	EID7886 PRPS1 exons were sequenced in the diagnosis and relapse samples of 358 B-Cell Childhood Acute Lymphoblastic Leukemia relapse patients (138 Chinese and 220 German). PRPS1 S103T was detected only at rel… (full text at CIViC) PMID 25962120 · Li et al., 2015 · Open in CIViC	civic
PRPS1 S103T	Lometrexol + MercaptopurineCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID7912 Treatment with the GART inhibitor, Lometrexol (de novo purine synthesis inhibitor), sensitized Reh cells overexpressing PRPS1 S103T to 6-MP as evidenced by significant reduction of the cell line's 6-M… (full text at CIViC) PMID 25962120 · Li et al., 2015 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.